Filing and business context
The supplied filing is a Form 10-Q for the quarter ended March 31, 2021. Although the request identifies Dominari Holdings Inc., the filing itself identifies the registrant as Aikido Pharma Inc. (ticker AIKI); confirm the issuer before relying on this summary.
Aikido described itself as a pre-revenue biotechnology company developing oncology and antiviral candidates through university partnerships and licenses. Its programs included candidates for pancreatic cancer, AML, ALL, and multiple viral infections. It also held investments, including marketable securities and a convertible note.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 or comparison |
|---|---|---|
| Revenue | No revenue reported | No revenue reported; management said it did not expect product revenue until a candidate is fully developed, potentially years away |
| Operating expenses | $2.318 million | $2.399 million |
| Operating loss | $2.318 million | $2.399 million |
| Other expense | $1.644 million | $5.934 million |
| Net loss | $3.962 million | $8.333 million |
| Basic and diluted loss per share | $0.07 | $0.91 |
| Net cash used in operating activities | $1.053 million | $1.448 million |
Revenue-based margins are not meaningful because the company reported no revenue. Lower Q1 2021 net loss chiefly reflected a smaller loss from the change in fair value of an investment in Hoth Therapeutics; this was partly offset by higher losses on marketable securities. The company reported a $1.339 million loss on marketable securities, including $2.049 million of unrealized losses, offset in part by realized gains and dividend income.
At March 31, 2021, cash and cash equivalents were $7.981 million and marketable securities were $92.426 million. Total current assets were $102.904 million; total assets were $104.931 million. Total liabilities were $0.559 million, all current, with no debt reported. Stockholders’ equity was $104.372 million. The resulting current-asset cushion was substantial, though much of it was held in securities rather than cash.
Operating activities used $1.053 million of cash; investing activities used $71.754 million, mainly reflecting marketable-security purchases and a $2.0 million convertible-note purchase. Financing activities provided $78.073 million. Ending cash was $7.981 million, up from $2.715 million at year-end 2020.
Material changes and notable transactions
- A February public offering and partial overallotment sold 53,905,927 common shares, producing approximately $78.0 million in net proceeds. The balance-sheet common shares outstanding rose from 34.9 million at December 31, 2020 to 89.5 million at March 31, 2021, a major increase in share count.
- The offering included underwriter warrants for up to 4,312,473 shares, exercisable at $2.00 per share for five years. Total warrants outstanding were 5,868,367 at quarter-end.
- In January, the company purchased a $2.0 million, 8% Convergent Therapeutics convertible note due January 29, 2023. It reported $27,000 of accrued interest and a $2.027 million carrying value.
- The company entered a Silo Pharma patent license arrangement for cancer-related psilocybin applications, involving 625,000 restricted shares and a $0.5 million cash payment; the license also carries a 2% royalty on defined net sales.
Outlook, risks, and controls
Management said the offering proceeds and available resources were expected to fund operations for at least the next 12 months from issuance of the financial statements. It planned to preserve and manage cash, pursue additional licenses, and seek research and commercialization partnerships. The filing provides no product-development timetable or quantified financial guidance.
- The company remains dependent on external financing and investment resources while it has little or no revenue; management warned that product revenue may be years away.
- Management said COVID-19 could adversely affect financial position, operating results, or the search for drug candidates, but the impact could not be determined. No related adjustments were recorded.
- Disclosure controls were deemed not effective at March 31, 2021 because of material weaknesses, including inadequate segregation of duties and insufficient controls to ensure material transactions and developments were reflected in the financial statements. No material control changes were reported during the quarter.
- The company reported no material active or pending legal proceedings beyond routine matters and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm issuer identity: the filing names Aikido Pharma Inc., not Dominari Holdings Inc.
- Review dilution from the offering, warrants, options, and other potentially dilutive securities; loss-per-share calculations excluded potential dilution because it was antidilutive.
- Assess the composition, liquidity, valuation, and market risk of the large marketable-securities portfolio and the Level 3 convertible note.
- Track cash use, operating runway, and whether the stated 12-month funding expectation remains current.
- Review remediation of the disclosed material weaknesses and the progress, costs, and evidence supporting the company’s preclinical pipeline claims.